Clinical Trial Update: Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of alemtuzumab for Waldenström's macroglobulinemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Lymphoma | Phase 2 | Status: WITHDRAWN